Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus

Annals of the Rheumatic Diseases

Volumn 68, Issue 6, 2009, Pages 997-1002

  Morel, J ^a,b   Roubille, C ^a   Planelles, L ^c   Rocha, C ^d   Fernandez, L ^c   Lukas, C ^a   Hahne, M ^e   Combe, B ^b  

^a UNIV MONTPELLIER   (France)

^b INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

^c CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

^e Lapeyronie Teaching Hospital ^*

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; AZATHIOPRINE; B CELL ACTIVATING FACTOR; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOUBLE STRANDED DNA ANTIBODY; HYDROXYCHLOROQUINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HUMAN; MALE; MEDICAL RECORD; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ACUTE DISEASE; ADULT; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; B-CELL ACTIVATING FACTOR; CASE-CONTROL STUDIES; DNA; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13; YOUNG ADULT;

EID: 67449162076     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.090928     Document Type: Article

References (23)

1. Merrill JT, Erkan D, Buyon JP. Challenges in bringing the bench to bedside in drug development for SLE. Nat Rev Drug Discov 2004;3:1036-1046 (Pubitemid 39642366)
2. Dillon SR, Gross JA, Ansell SM, Novak AJ. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006;5:235-246 (Pubitemid 43336036)
3. Mackay F, Kalled SL. TNF ligands and receptors in autoimmunity: an update. Curr Opin Immunol 2002;14:783-790 (Pubitemid 35292427)
4. Lopez-Fraga M, Fernandez R, Albar JP, Hahne M. Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep 2001;2:945-951 (Pubitemid 33040585)
5. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000;404:995-999 (Pubitemid 30243593)
6. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001;166:6-10. (Pubitemid 32038409)
7. Koyama T, Tsukamoto H, Miyagi Y, Himeji D, Otsuka J, Miyagawa H, et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005;64:1065-1067 (Pubitemid 40909524)
8. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Roschke V, et al. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2004;63:1096-1103 (Pubitemid 39120361)
9. Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol 2000;53:424-432 (Pubitemid 30396463)
10. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-291
11. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-640
12. Planelles L, Carvalho-Pinto CE, Hardenberg G, Smaniotto S, Savino W, Gomez-Caro R, et al. APRIL promotes B-1 cell-associated neoplasm. Cancer Cell 2004;6:399-408. (Pubitemid 39361440)
13. Planelles L, Castillo-Gutiérrez S, Medema JP, Morales-Luque A, Merle-Béral H, Hahne M. APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survival. Hematologica 2007;92:1284-1285 (Pubitemid 350144199)
14. Ali YM, Urowitz MB, Ibanez D, Gladman DD. Monoclonal gammopathy in systemic lupus erythematosus. Lupus 2007;16:426-429 (Pubitemid 47122216)
15. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001;44:1313-1319 (Pubitemid 32537529)
16. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003;48:3475-3486 (Pubitemid 37531913)
17. Vallerskog T, Heimburger M, Gunnarsson I, Zhou W, Wahren-Herlenius M, Trollmo C, et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006;8:R167.
18. Mannik M, Merrill CE, Stamps LD, Wener MH. Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. J Rheumatol 2003;30:1495-1504 (Pubitemid 36835445)
19. Grootscholten C, van Bruggen MC, van der Pijl JW, de Jong EM, Ligtenberg G, Derksen RH, et al. Deposition of nucleosomal antigens (histones and DNA) in the epidermal basement membrane in human lupus nephritis. Arthritis Rheum 2003;48:1355-1362 (Pubitemid 36554534)
20. Cervera R, Font J, Shoenfeld Y. European Working Party on Systemic Lupus Erythematosus: a 15-year report. Autoimmun Rev 2006;5:549-553 (Pubitemid 44486952)
21. Kalled SL. Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin Immunol 2006;18:290-296 (Pubitemid 44382641)
22. Ding C, Jones G. Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline. Curr Opin Investig Drugs 2006;7:464-472 (Pubitemid 43772987)
23. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007;56:4142-4150 (Pubitemid 350262342)